Diamyd Medical AB (publ)

DB:DMN Stock Report

Market Cap: €164.4m

Diamyd Medical Management

Management criteria checks 3/4

Diamyd Medical's CEO is Ulf Hannelius, appointed in Apr 2016, has a tenure of 8.75 years. total yearly compensation is SEK3.43M, comprised of 70.4% salary and 29.6% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth €446.99K. The average tenure of the management team and the board of directors is 5 years and 14.5 years respectively.

Key information

Ulf Hannelius

Chief executive officer

SEK 3.4m

Total compensation

CEO salary percentage70.4%
CEO tenure8.8yrs
CEO ownership0.3%
Management average tenure5yrs
Board average tenure14.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ulf Hannelius's remuneration changed compared to Diamyd Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024SEK 3mSEK 2m

-SEK 152m

May 31 2024n/an/a

-SEK 140m

Feb 29 2024n/an/a

-SEK 120m

Nov 30 2023n/an/a

-SEK 116m

Aug 31 2023SEK 3mSEK 2m

-SEK 116m

May 31 2023n/an/a

-SEK 119m

Feb 28 2023n/an/a

-SEK 115m

Nov 30 2022n/an/a

-SEK 99m

Aug 31 2022SEK 3mSEK 2m

-SEK 104m

May 31 2022n/an/a

-SEK 91m

Feb 28 2022n/an/a

-SEK 106m

Nov 30 2021n/an/a

-SEK 83m

Aug 31 2021SEK 3mSEK 2m

SEK 60m

May 31 2021n/an/a

SEK 74m

Feb 28 2021n/an/a

SEK 99m

Nov 30 2020n/an/a

SEK 121m

Aug 31 2020SEK 3mSEK 2m

SEK 10m

May 31 2020n/an/a

SEK 13m

Feb 29 2020n/an/a

SEK 13m

Nov 30 2019n/an/a

-SEK 35m

Aug 31 2019SEK 2mSEK 1m

-SEK 37m

May 31 2019n/an/a

-SEK 38m

Feb 28 2019n/an/a

-SEK 43m

Nov 30 2018n/an/a

-SEK 42m

Aug 31 2018SEK 2mSEK 1m

-SEK 44m

Compensation vs Market: Ulf's total compensation ($USD307.53K) is below average for companies of similar size in the German market ($USD888.91K).

Compensation vs Earnings: Ulf's compensation has increased whilst the company is unprofitable.

CEO

Ulf Hannelius (49 yo)

8.8yrs

Tenure

SEK 3,431,000

Compensation

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...

Leadership Team

NamePositionTenureCompensationOwnership
Ulf Hannelius
CEO & President8.8yrsSEK 3.43m0.27%
€ 447.0k
Anna Styrud
Chief Financial Officerno datano data0.14%
€ 225.1k
Martina Widman
Chief Operating Officer2.6yrsno data0.012%
€ 19.7k
Anton Lindqvist
Chief Scientific Officer7.3yrsno datano data
Maja Johansson
Chief Operating Officer of Manufacturing Site2yrsno data0.0024%
€ 3.9k

5.0yrs

Average Tenure

49yo

Average Age

Experienced Management: DMN's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ake Lernmark
Member of the Scientific Advisory Board29yrsno datano data
David Leslie
Member of the Scientific Advisory Board26yrsno datano data
Daniel Kaufman
Member of the Scientific Advisory Board29yrsno datano data
Anders Essen-Möller
Independent Chairman29yrsSEK 1.09m3.78%
€ 6.2m
Mark Atkinson
Chairman of Scientific Advisory Board & Independent Director28yrsSEK 175.00k0.016%
€ 26.5k
Karin Hehenberger
Independent Director3.8yrsSEK 125.00k0.0096%
€ 15.8k
Erik Nerpin
Independent Vice Chairman13yrsSEK 214.00k0.056%
€ 92.8k
Torbjörn Bäckström
Independent Director8yrsSEK 138.00k0.00096%
€ 1.6k
Maria-Teresa Essen-Möller
Independent Director16yrsSEK 164.00k1.31%
€ 2.2m
Karin Rosen
Independent Director1.8yrsSEK 125.00k0.000010%
€ 16.4
Emily Sims
Member of Scientific Advisory Boardless than a yearno datano data
Alice Long
Member of Scientific Advisory Boardno datano datano data

14.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: DMN's board of directors are seasoned and experienced ( 14.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 13:18
End of Day Share Price 2025/01/17 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diamyd Medical AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonPenser Access